Loading company…
SIGA Technologies, based in New York, develops antiviral treatments for smallpox and mpox, led by its TPOXX product.
Founded in 1995 and based in New York, US, SIGA Technologies is a biopharmaceutical company developing antiviral treatments for threats caused by orthopoxviruses. Its TPOXX product was the first antiviral approved by the FDA for smallpox and is also used for mpox. The company reported global revenues of USD 138.72 mn for 2024, mainly from direct sales to government entities. Phil Gomez is CEO, and the company has raised USD 20.00 mn across 10 deals, including a USD 7.70 mn grant in August 2011.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in